Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Crit Rev Food Sci Nutr ; 62(20): 5462-5475, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-33724098

RESUMEN

Elevated plasma levels of homocysteine (Hcy) are a recognized risk factor for stroke. This relationship represents one aspect of the debated `Hcy hypothesis'. Elevated Hcy may be an independent and treatable cause of atherosclerosis and thrombotic vascular diseases. Further observations indicate that proper dietary supplementation with B-vitamins decreases total plasma Hcy concentrations and may be an effective intervention for stroke prevention. Metabolic vitamin B12 deficiency is a nutritional determinant of total Hcy and stroke risk. Genetic factors may link B vitamins with stroke severity due to the impact on Hcy metabolism of polymorphism in the genes coding for methylenetetrahydrofolate reductase, methionine-synthase, methionine synthase reductase, and cystathionine ß-synthase. Several meta-analyses of large randomized controlled trials exist. However, they are not completely in agreement about B vitamins' role, particularly folic acid levels, vitamin B12, and B6, in lowering the homocysteine concentrations in people at high stroke risk. A very complex relationship exists between Hcy and B vitamins, and several factors appear to modify the preventive effects of B vitamins in stroke. This review highlights the regulating factors of the active role of B vitamins active in stroke prevention. Also, inputs for further large, well-designed studies, for specific, particularly sensitive subgroups are given.


Asunto(s)
Hiperhomocisteinemia , Accidente Cerebrovascular , Complejo Vitamínico B , Ácido Fólico , Homocisteína , Humanos , Hiperhomocisteinemia/complicaciones , Hiperhomocisteinemia/tratamiento farmacológico , Accidente Cerebrovascular/prevención & control , Vitamina B 12 , Complejo Vitamínico B/farmacología , Complejo Vitamínico B/uso terapéutico
2.
Arch Toxicol ; 94(6): 1879-1897, 2020 06.
Artículo en Inglés | MEDLINE | ID: mdl-32388818

RESUMEN

Arsenic (As) is widely used in the modern industry, especially in the production of pesticides, herbicides, wood preservatives, and semiconductors. The sources of As such as contaminated water, air, soil, but also food, can cause serious human diseases. The complex mechanism of As toxicity in the human body is associated with the generation of free radicals and the induction of oxidative damage in the cell. One effective strategy in reducing the toxic effects of As is the usage of chelating agents, which provide the formation of inert chelator-metal complexes with their further excretion from the body. This review discusses different aspects of the use of metal chelators, alone or in combination, in the treatment of As poisoning. Consideration is given to the therapeutic effect of thiol chelators such as meso-2,3-dimercaptosuccinic acid, sodium 2,3-dimercapto-1-propanesulfonate, 2,3-dimercaptopropanol, penicillamine, ethylenediaminetetraacetic acid, and other recent agents against As toxicity. The review also considers the possible role of flavonoids, trace elements, and herbal drugs as promising natural chelating and detoxifying agents.


Asunto(s)
Antídotos/uso terapéutico , Intoxicación por Arsénico/tratamiento farmacológico , Arsenicales/efectos adversos , Quelantes/uso terapéutico , Contaminantes Ambientales/efectos adversos , Preparaciones de Plantas/uso terapéutico , Animales , Antídotos/efectos adversos , Intoxicación por Arsénico/etiología , Intoxicación por Arsénico/metabolismo , Arsenicales/metabolismo , Quelantes/efectos adversos , Exposición a Riesgos Ambientales , Contaminantes Ambientales/metabolismo , Humanos , Preparaciones de Plantas/efectos adversos , Medición de Riesgo , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA